leisure time -WSS

leisure time

author：hotspot 2025-10-03 00:07:51 - browse：73847

Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.

For more on what we cover, here’s the story on addiction medicine; here’s the latest on biotech financing; here’s more on Novo Nordisk’s oral obesity treatment; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Clinical trials giant ICON acquires HumanFirst

WSS

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

Kenai launches with $82 million for Parkinson’s stem cell therapy

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Flu vaccine offering decent levels of protection this winter, new data show

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

knowledge

leisure time

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

EMA weighs against approval for Mirati's lung cancer drug

Tori Bowie and the unacceptable rates of Black maternal death

EMA weighs against approval for Mirati's lung cancer drug

New air purifier tech could be key to improving indoor air quality

Clinical trials giant ICON acquires HumanFirst

Hepatitis C has a cure — but many Americans still lack access to it

Medical device lobby: We're tired of waiting on Medicare coverage

Trump demands the U.S. pay no more for drugs than other countries … again

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

leisure time

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

In search for therapies for solid tumors, companies turn to claudin

Reframing the conversation around gain

FDA does about

What is the Turing Test that determines if computers can think?

Pfizer's RSV vaccine recommended for approval in Europe

focus

leisure time

leisure time

explore